These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31032673)

  • 1. Do poor-responder patients undergoing IVF benefit from splitting and increasing the daily gonadotropin dose?
    Ezra O; Haas J; Nahum R; Maman E; Cohen Y; Segev-Zahav A; Orvieto R
    Gynecol Endocrinol; 2019 Oct; 35(10):890-893. PubMed ID: 31032673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Do poor-responder patients benefit from increasing the daily gonadotropin dose from 300 to 450 IU during controlled ovarian hyperstimulation for IVF?].
    Haas J; Zilberberg E; Kedem A; Dar S; Orvieto R
    Harefuah; 2015 Feb; 154(2):114-7, 135. PubMed ID: 25856865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?
    Haas J; Zilberberg E; Machtinger R; Kedem A; Hourvitz A; Orvieto R
    Gynecol Endocrinol; 2015 Jan; 31(1):79-82. PubMed ID: 25223892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
    Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate.
    Fabris AM; Cruz M; Legidos V; Iglesias C; Muñoz M; García-Velasco JA
    Reprod Sci; 2017 Aug; 24(8):1221-1225. PubMed ID: 28715965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.
    Zhu X; Ye H; Fu Y
    Medicine (Baltimore); 2016 Jul; 95(28):e4193. PubMed ID: 27428219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the stimulation dose of rFHS in unexpected poor responders is not associated with better IVF outcome.
    Tutuncu L; Dundar O
    Ginekol Pol; 2012 Feb; 83(2):111-5. PubMed ID: 22568355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
    Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
    Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical significance of the ratio in FSH/LH of human menopausal gonadotropins in a programmed stimulation regimen for IVF-ET].
    Ikenaga H
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Nov; 47(11):1223-9. PubMed ID: 8543846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
    Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Protocol of GNRH antagonist in poor responders in IVF-ET cycles].
    Grzechocińska B; Fracki S; Marianowski P; Dworniak T; Bablok L; Marianowski L
    Ginekol Pol; 2003 Sep; 74(9):943-8. PubMed ID: 14674149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled ovarian stimulation using a long gonadotropin-releasing hormone antagonist protocol: a proof of concept and feasibility study.
    Weissman A; Ravhon A; Steinfeld Z; Nahum H; Golan A; Levran D
    Gynecol Obstet Invest; 2013; 76(2):113-8. PubMed ID: 23920048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.